Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Two important pancreatic studies: PRODIGE 24 and PREOPANC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.08.18
Views: 1005

Dr Kenneth Yu - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Yu speaks to ecancer at BEST OF ASCO® 2018 MIAMI SYMPOSIUM about the PRODIGE 24 study which concerned patients with resected pancreatic ductal adenocarcinomas.

He describes the clear-cut result of this study and thus his opinion that the standard of change should change on these patients, particularly for those patients who can tolerate a more intensive chemotherapy regimen.

He then discusses the PREOPANC study which looks at chemotherapy before and after, or only after surgery.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation